Recombinant HCG beta antibody
Quick Overview for Recombinant HCG beta antibody (ABIN5707874)
Target
See all HCG beta AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
Clone
-
-
Purpose
- Recombinant HCG-beta Antibody / Rabbit Monoclonal (azide and preservative free)
-
Purification
- Protein A affinity chromatography
-
Immunogen
- Recombinant protein was used as the immunogen for this recombinant HCG-beta antibody.
-
Isotype
- IgG, kappa
-
-
-
-
Application Notes
-
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the recombinant HCG-beta antibody to be titered up or down for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the recombinant HCG-beta antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- HCG beta
-
Alternative Name
- HCG-beta
-
Background
- This antibody reacts with a protein of 22 kDa, identified as beta subunit of HCG. It does not cross react with the alpha subunit. HCG is a glycoprotein which is secreted in large quantities by normal trophoblasts. It is present only in trace amounts in non-pregnant urine and sera but rises sharply during pregnancy. HCG is composed of two non-identical, non-covalently linked polypeptide chains designated as the alpha and beta subunits. The alpha subunit is identical to that of thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), and luteinizing hormone (LH). HCG-beta antibody detects cells and tumors of trophoblastic origin such as choriocarcinoma. Large cell carcinoma and adenocarcinoma of the lung demonstrate antibody positivity in 90 % and 60 % of cases respectively, 20 % of lung squamous cell carcinomas are positive. HCG expression by non-trophoblastic tumors may indicate aggressive behavior.
Target
-